8 / 49
OS (ITT Population)
Abstract ID: 8717
Erlotinib
(n=51)
NP
(n=51)
Patients with events, n (%)
3 ( 5.9)
13 (25.5)
Median OS
, months (95% CI)
NR
NR
HR
(95% CI)
0.165
( 0.047, 0.579)
P-value (log-rank test)
0.001
P-value (stratified log-rank test)
0.002
0.0
0.2
0.4
0.6
0.8
1.0
OS probability
0
12
24
36
48
60
Patients at Risk
Erlotinib
NP
51
51
44
34
41
30
23
16
0
0
4
5
Erlotinib
NP
Censored
Time (Months)
Efficacy and Safety of Erlotinib vs Vinorelbine/Cisplatin as Adjuvant Therapy for Stage IIIA
EGFR
Mutant NSCLC Patients (EVAN, NCT01683175)